naltrexone has been researched along with Nervous System Disorders in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (16.67) | 18.7374 |
1990's | 2 (33.33) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 1 (16.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Jeong, C; Jeong, H; Jeong, S; Kim, SJ; Lee, J; Lee, S; Yoo, KY | 1 |
Brune, A; Luger, TA; Metze, D; Ständer, S | 1 |
Meyers, CA; Talpaz, M; Valentine, AD | 1 |
Coudoré-Civiale, MA; Courteix, C; Eschalier, A; Fialip, J; Privat, AM; Zajac, JM | 1 |
Williams, A | 1 |
2 trial(s) available for naltrexone and Nervous System Disorders
Article | Year |
---|---|
[Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nervous System Diseases; Pruritus; Tachyphylaxis; Treatment Outcome | 2004 |
Treatment of neurotoxic side effects of interferon-alpha with naltrexone.
Topics: Adult; Female; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Naltrexone; Nervous System Diseases; Thrombocythemia, Essential | 1995 |
4 other study(ies) available for naltrexone and Nervous System Disorders
Article | Year |
---|---|
Neuroprotective effects of remifentanil against transient focal cerebral ischemia in rats.
Topics: Anesthetics, Intravenous; Animals; Blood Pressure; Blotting, Western; Carbon Dioxide; Dose-Response Relationship, Drug; Infarction, Middle Cerebral Artery; Interleukin-6; Ischemic Attack, Transient; Male; Mitogen-Activated Protein Kinases; Naltrexone; Narcotic Antagonists; Nervous System Diseases; Neuroprotective Agents; Piperidines; Rats; Rats, Sprague-Dawley; Remifentanil; Reperfusion Injury; Tumor Necrosis Factor-alpha | 2012 |
[Antipuritic therapy with naltrexone].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nervous System Diseases; Pruritus; Tachyphylaxis; Treatment Outcome | 2005 |
Spinal effect of a neuropeptide FF analogue on hyperalgesia and morphine-induced analgesia in mononeuropathic and diabetic rats.
Topics: Analgesia; Analgesics; Analgesics, Opioid; Animals; Behavior, Animal; Diabetes Mellitus, Experimental; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hyperalgesia; Injections, Spinal; Male; Morphine; Naltrexone; Narcotic Antagonists; Nervous System Diseases; Oligopeptides; Pain; Rats; Rats, Sprague-Dawley; Somatostatin; Time Factors; Vocalization, Animal | 1999 |
Primary care of parenteral substance abusers.
Topics: Acquired Immunodeficiency Syndrome; Administration, Intranasal; Antibodies, Viral; Body Weight; Cocaine; Female; Heart Diseases; Hepatitis; Heroin Dependence; HIV Antibodies; Humans; Injections, Intradermal; Injections, Intravenous; Kidney Diseases; Male; Menstruation Disturbances; Methadone; Naltrexone; Nervous System Diseases; Primary Health Care; Respiratory Tract Diseases; Substance-Related Disorders | 1986 |